Navigation Links
Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study of Amigal(TM) for Fabry Disease
Date:2/11/2010

CRANBURY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.  The Company also presented encouraging data from preclinical studies evaluating the combination of pharmacological chaperones and enzyme replacement therapy (ERT) for Fabry disease and Pompe disease as well as from preclinical studies examining the use of pharmacological chaperones for the treatment of Parkinson's disease.  

Phase 2 Extension Study Overview

Twenty-six subjects completed either 12 or 24 weeks of treatment with migalastat HCl during the initial Phase 2 studies and twenty-three subjects enrolled in a separate, voluntary long-term extension study designed to evaluate the long-term safety and efficacy of migalastat HCl.  Over the course of the initial Phase 2 and extension studies, fifteen subjects have been treated with migalastat HCl for approximately 2-3 years and eight subjects have been treated with migalastat HCl for more than 3 years.  Twenty-one subjects continue to receive treatment in the ongoing extension study.

Preliminary Data Update from Long-term Phase 2 Extension Study

During the course of the extension study, treatment with migalastat HCl has been generally well-tolerated, with no drug-related serious adverse events.  The most common adverse events were headache, arthralgia and diarrhea.  

Renal function is being evaluated by two measures in the extension study, estimated glomerular filtrat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
2. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
3. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
5. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
6. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
7. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
8. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
9. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
10. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
(Date:8/29/2014)... 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products Implements ... the SAM Junctional Tourniquet.  Photo ... Medical Products announced today that it has begun ... a potential issue with a clip used to ... application of the SAM Junctional Tourniquet (SJT).  The ...
(Date:8/29/2014)... 2014  A Boston Scientific Corporation (NYSE: ... removability and preliminary long term stricture resolution of ... August issue of the peer-reviewed journal, Gastroenterology. ... being conducted in 11 countries and five continents, ... stents (FCSEMS) after extended indwell (i.e., up to ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... LAKES, N.J., Feb. 21, 2012 Fourth-Quarter ... share (EPS) of $1.08 increased 22.7 percent; Diluted EPS ... the pending merger with Express Scripts, Inc., increased 29.5 ... diluted EPS, excluding all intangible amortization and merger-related expenses, ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a ... announced today that it has received a request ... Medicinal Products (CHMP) on Glybera® (alipogene tiparvovec) by March ... on January 30, 2012 that the European Commission ...
Cached Medicine Technology:Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 2Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 3Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 4Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 5Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 6Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 7Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 8Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 9Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 10Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 11Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 12Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 13Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 14Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 15Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 16Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 17Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 18Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 19Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 20Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 21Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 22Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 23Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 24Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 25Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 26Medco Delivers Record Fourth-Quarter and Full-Year 2011 Earnings 27Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera® 2Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera® 3Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera® 4
(Date:9/2/2014)... in the U.S. has led to public debate about ... alcohol. In January, President Obama also publically stated he ... alcohol. Despite the recent shift in views toward marijuana, ... are not well understood. , Now a ... among US High School Seniors: A Comparison of Alcohol ...
(Date:9/2/2014)... 2 September 2014: A simple awareness campaign in general ... to research presented at ESC Congress today by Professor ... fibrillation (AF) is the most common cardiac arrhythmia. It ... and the risk of stroke risk by five-fold. Similarly, ... 4 cases. However, AF is often overlooked and diagnosed ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and home medical ... of its new office to be located in Greer, ... Suite D, Greer, SC 29651. This new location will ... convenient location in the Greenville area. , “This is ... hospitals and patients we serve, to ensure that we ...
(Date:9/2/2014)... September 02, 2014 September 2014 – The ... gone. But even though men shave daily – and commit ... rough and irritated skin isn’t inevitable, according to Joshua ... , For decades, skin care was something in which ... surge in men of all ages who realize that their ...
(Date:9/1/2014)... Windows web hosting provides a Windows based server ... recent years, and the new demand has resulted in ... that offer a variety of different services at very ... professional Windows web hosting suppliers from the USA and ... suppliers for webmasters who want to buy high quality ...
Breaking Medicine News(10 mins):Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 2Health News:Rough Isn’t Rugged in Men’s Skin: Dermatology specialist Dr. Joshua Fox with Advanced Dermatology PC offers tips on easy skin maintenance for men 3Health News:SEO Hosting Review Site Top10BestSEOHosting.com: Best Windows Web Hosting Suppliers From the USA Now Unveiled 2
... the breathing passage, which results due to smoking is ... 2020. // ,Called Chronic Obstructive Pulmonary ... chronic-obstructive bronchitis and emphysema of the lungs. ... swelling of the mucous membrane and emphysema decomposes lung ...
... urinalysis can reveal very much about the health condition ... simple diagnostic procedure should not be overlooked. // ... Prince Charles Hospital said by examining a patient's urine ... taking certain medications or were being over-administered, reported ABC ...
... breast cancer victims is denied by the NHS to victims ... private medical insurers have saved their day by pitching in. ... available this drug to almost 100 women, who have been ... the drug available in 30 such cases. ,It ...
... appropriate climate where new ideas can thrive. But it ... There are a variety of social problems. To solve ... and resources. Collaboration is an essential element that holds ... application for the resulting discovery. Collaboration should be among ...
... in favor of the rise in Medicare bulk billing, which ... Federal Health Minister Tony Abbott released some alarming statistics that ... nationally. ,According to Dr Kim Bulwinkel, from AMA ... seeing more patients, in order to make it a feasible ...
... (HFM) disease has taken the life of another 14-month-old toddler in ... Sarawak has reached six since the outbreak. ,Deputy Chief ... a total of 82 children have been admitted to hospitals for ... state Disaster Management Committee, said that about 213 new cases were ...
Cached Medicine News:Health News:Colour Of Urine Can Reveal The Health Status Of The Patients 2Health News:Health Care System in US Needs a Change 2
... the worlds leading medical technology company ... management for more than a decade, ... Timer. The ACT Plus System is ... to determine coagulation endpoints in whole ...
... techniques have largely replaced the use of plates and ... use of rods or pins in the forearm or ... been no way to lock the pins or hold ... non-locked nail is back out of the implant. The ...
... Atlas+ HF ICD is designed to provide the ... quality of life. The Atlas+ HF ICD is ... therapy (CRT), and it packs its power into ... can. In addition to its high energy, the ...
... Tibial Nail System is designed ... of existing implants and expand ... nails. It is available in ... and lengths and can be ...
Medicine Products: